Summary
The provided FDA label excerpts do not include any information about Paxil's first approval/launch date in the U.S. in 1992. Therefore, the AI-generated claims about FDA approval date and marketing/clinical use in 1992 are unsupported by the supplied prescribing information.
Category Scores
Accurate Statements
The label language supports that Paxil (PAXIL) and other antidepressants may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed, and that Paxil is not for use in children.
Supported by Medication Guide (“24 years of age and younger… especially within the first few months… when the dose is changed. PAXIL is not for use in children.”) and Warnings and Precautions (5.1).
The label language supports that PAXIL is not approved for use in pediatric patients (safety/effectiveness not established; effectiveness not demonstrated in trials).
Supported by Warnings and Precautions (5.1) and Pediatric Use (8.4) (“safety and effectiveness… have not been established… PAXIL is not approved for use in pediatric patients.” and trial effectiveness statements).
Unsupported Statements
Paxil (generic name: paroxetine) was first approved and launched in the U.S. in 1992.
The supplied prescribing information excerpts do not include approval/launch dates; no label text provided supports a 1992 approval/launch statement.
The FDA approval date for Paxil was 1992.
No FDA approval date is present in the provided label excerpts; the supplied text only references a “Revised: 11/2024” and does not state an approval date.
Paxil began moving into clinical use and marketing in 1992.
The supplied prescribing information excerpts do not discuss clinical use or marketing start dates.
Contradictions
Important Omissions
Whether Paxil's FDA approval date is 1992 cannot be determined from the provided label excerpts; if the AI intended to provide label-backed dating, the supporting label section is missing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-supported safety claims relate to suicidal thoughts/behaviors and pediatric non-approval; however, the unsupported historical dating claims do not directly change labeled safety recommendations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsupported historical/approval/marketing date claims (1992) are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict statements to information present in the supplied label excerpts (e.g., suicidal thoughts/behaviors warning and pediatric non-approval) and remove or replace approval/launch/marketing date claims unless the label text containing those dates is provided.